Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Glioblastoma 276Brain Neoplasms 169Glioma 139Central Nervous System Neoplasms 85Gliosarcoma 79Astrocytoma 74Neuroblastoma 64Oligodendroglioma 42Neoplasms 40Breast Neoplasms 38Recurrence 37Carcinoma, Non-Small-Cell Lung 31Medulloblastoma 27Melanoma 26Ovarian Neoplasms 24Lymphoma 21Diffuse Intrinsic Pontine Glioma 21Sarcoma 19Neoplasm Metastasis 19Lung Neoplasms 18Colorectal Neoplasms 17Rhabdomyosarcoma 16Osteosarcoma 16Meningeal Carcinomatosis 15Ependymoma 15Pancreatic Neoplasms 14Meningioma 14Sarcoma, Ewing 13Stomach Neoplasms 12Esophageal Neoplasms 12

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenomatous Polyposis Coli × CNS × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡